Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 16,859 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Cyclosporine, Methotrexate, Photopheresis, Mycofenolate mofetil, Pentostatin, allogeneic bone marrow, peripheral blood stem cell, Total body irradiation; Drug · Procedure · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 6
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more

Conditions: Fibromyalgia
Interventions: Duloxetine, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 33
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions: Omacetaxine Mepesuccinate, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: etanercept; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Long COVID
Interventions: WATER+CT, Usual Care; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: HIV Infections
Interventions: Dapivirine Vaginal Ring, Maraviroc Vaginal Ring, Placebo Vaginal Ring, Dapivirine-Maraviroc Vaginal Ring; Drug · Other
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: MPS IV A, Mucopolysaccharidosis IVA, Morquio A Syndrome
Interventions: Not listed
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Not listed
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Oakland, California • Chicago, Illinois

Conditions: Blood Pressure
Interventions: Potassium Chloride; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 35 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Dry Eye Syndromes
Interventions: Refresh Optive® Gel Drops, REFRESH LIQUIGEL®; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Petaluma, California • San Diego, California • Bangor, Maine + 7 more

Conditions: Diabetes Mellitus Type 2
Interventions: Aleglitazar, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 7,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 221
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 181 more

Conditions: Polycystic Ovary Syndrome
Interventions: Vitamin D, Placebo; Dietary Supplement · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Chronic Iron Overload Due to Transfusion-dependant Anemias
Interventions: Deferasirox dispersible tablet, Defearisox film-coated tablet; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Orange, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Carpal Tunnel Syndrome, Median Nerve Injury
Interventions: Cooling, Heating, Exercising, Typing, Using a mouse, Cooking; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • Columbus, Ohio

Conditions: Traumatic Brain Injury With Brief Loss of Consciousness, Post-Concussion Syndrome
Interventions: Hyperbaric oxygen (HBO2) at 1.5 atms, Sham control 1.2 atms; Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Colorado Springs, Colorado • Fort Carson, Colorado • Jacksonville, North Carolina + 2 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort®, Standard Care; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Morehead City, North Carolina

Conditions: Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 80 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obstructive Sleep Apnea (OSA), Snoring, Sleep Quality
Interventions: Exercise; Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions: 124I AT-01; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tendonitis, Carpal Tunnel Syndrome, Cumulative Trauma Disorders, Overuse Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Signs and Symptoms, Respiratory
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Adenocarcinoma, Prostate Neoplasms, Prostate Cancer, Renal Cell Carcinoma, Von Hippel Lindau Disease
Interventions: EM Tracking; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 3,894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: 22Q11.2 Deletion Syndrome
Interventions: ZYN002; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Ro 24-7429; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Search by objective public record fields.

Transcranial Magnetic Stimulation (TMS) for CRPS

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

Water-based Activity to Enhance Recovery in Long COVID-19

Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)

Pre-ESRD Syndrome in High Risk African Americans

A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Sonographic Measurement of Intraneural Blood Flow in the Median Nerve

mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease

The Impact of Technology in Obstructive Sleep Apnea Myofunctional Therapy

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

Work and Health Disparities Among Rural Women

Improved Patient Safety Through Continuous Bi-channel RR and SpO2 Monitoring With Masimo Patient SafetyNet

Use of Tracking Devices to Locate Abnormalities During Invasive Procedures

Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma